Pharmacokinetics of metronidazole in patients with alcoholic liver disease.
The pharmacokinetics of metronidazole was evaluated in eight patients with alcoholic liver disease. Metronidazole (7.5 mg/kg) was administered to each patient intravenously. Serial blood samples were obtained after the dose. Serum metronidazole concentrations were determined by high-performance liquid chromatography. The following pharmacokinetic parameters (mean +/- standard deviations) were obtained: half-life, 18.31 +/- 6.06 h; elimination rate constant, 0.042 +/- 0.013 h-1; volume of distribution, 0.77 +/- 0.16 liters/kg; and total body clearance, 0.51 +/- 0.11 ml/min per kg. Compared with subjects with normal liver function, patients with liver disease showed a reduction in drug elimination rate and total body clearance. The half-life of metronizadole in serum and volume of distribution were increased. Large variations of these parameters were also observed among the patients. On the basis of these observations, a reduced dose of metronidazole should be given to patients with alcoholic liver disease to avoid accumulation of metronidazole and its metabolites. Monitoring of drug concentration in serum may also be necessary to optimize therapy.
College of Pharmacy, University of Illinois, Chicago 60612.
A H
AH
Lau
R
R
Evans
C W
CW
Chang
R
R
Seligsohn
D000328:Adult; D005260:Female; D006207:Half-Life; D006801:Humans; D008108:Liver Diseases, Alcoholic / Q000378:metabolism*; D008297:Male; D008795:Metronidazole / Q000493:pharmacokinetics*; D008875:Middle Aged
D008795:Metronidazole